Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bleomycin electroporation therapy

Drug Profile

Bleomycin electroporation therapy

Alternative Names: NeoPulse; OMS ElectroChemotherapy; SECTA therapy; Selective Electrochemical Tumor Ablation therapy

Latest Information Update: 24 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Inovio Pharmaceuticals
  • Class Antineoplastics; Cytostatic antibiotics; Glycopeptides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Suspended Breast cancer; Head and neck cancer; Malignant melanoma
  • Discontinued Basal cell cancer; Kaposi's sarcoma; Liver cancer; Pancreatic cancer

Most Recent Events

  • 29 Sep 2017 Inovio withdraws a phase III trial in Head and neck cancer prior to enrolment in USA and European Union based on the Data Monitoring Committee's recommendation(Intratumoural) (NCT00198315)
  • 28 Sep 2011 OncoSec plans to conduct further clinical studies, based on positive results from clinical trials in Head and neck cancer and Breast cancer
  • 26 Sep 2011 Final adverse events and efficacy data from a phase I trial in Breast cancer released by OncoSec Medical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top